Back to Search
OMAR IQBAL, MD
MD
Family Medicine Physician
NPI: 1275252454IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
78016(AZ)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
OTHER
Class of 2022
Research & Publications (20)
Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases.
PMID 19208592·J Rheumatol·2009
8-other
Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
PMID 18974698·Int Angiol·2008
4-observational
Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
PMID 18506123·Int Angiol·2008
6-review
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
PMID 18671707·Br J Haematol·2008
4-observational
Contaminant in the recalled unfractionated heparin preparations: where is the problem?
PMID 18565985·Clin Appl Thromb Hemost·2008
7-preclinical
Pre-natal diagnosis of caudal regression syndrome.
PMID 17686358·J Coll Physicians Surg Pak·2007
8-other
Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis.
PMID 17911187·Clin Appl Thromb Hemost·2007
7-preclinical
Clinical applications of bioinformatics, genomics, and pharmacogenomics.
PMID 16671404·Methods Mol Biol·2006
6-review
Comparative tissue factor pathway inhibitor release potential of heparins.
PMID 15678271·Clin Appl Thromb Hemost·2005
4-observational
Pharmacogenomics and pharmacogenetics. 1st Spanish Congress on Pharmacogenomics and Pharmacogenetics, January 23-25, 2005, Valencia, Spain.
PMID 16013951·Pharmacogenomics·2005
8-other
Generic low molecular weight heparins: a significant dilemma.
PMID 16244760·Clin Appl Thromb Hemost·2005
8-other
Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in rats.
PMID 15497025·Clin Appl Thromb Hemost·2004
7-preclinical
Blood levels of nitric oxide, C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: pathophysiologic implications.
PMID 15497022·Clin Appl Thromb Hemost·2004
8-other
Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor.
PMID 14979411·Clin Appl Thromb Hemost·2004
5-case
Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
PMID 15085470·Semin Thromb Hemost·2004
4-observational
Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor.
PMID 15247979·Clin Appl Thromb Hemost·2004
8-other
Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants.
PMID 15497016·Clin Appl Thromb Hemost·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 11351 S FRONTAGE RD
YUMA, AZ 85367 - Phone
- (928) 336-4000
Quick Facts
- NPI
- 1275252454
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 4
- Publications
- 20
Are you this provider?
Claim Your Profile